HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Creutzfeldt-Jakob disease — Clinical Guidelines

Overview

Creutzfeldt-Jakob disease (CJD) is a rapidly progressive neurodegenerative disorder characterized by spongiform changes in the brain, leading to dementia and myoclonus. Variant CJD (vCJD) is linked to bovine spongiform encephalopathy (BSE) exposure 1 5.

Diagnosis

Clinical Criteria: Rapidly progressive dementia, myoclonus, and characteristic EEG findings (periodic sharp wave complexes) 14 16.

CSF Biomarkers: Elevated levels of 14-3-3 protein (high sensitivity), neuron-specific enolase (NSE), and S-100 protein can aid diagnosis 9.

EEG: Periodic epileptiform discharges are highly indicative but can be normal in some cases 14 16.

Histopathology: Brain biopsy or autopsy showing spongiform changes and prion protein deposition confirms diagnosis 15 22.

False Negatives: Sedative therapy may induce false negative 14-3-3 tests 2.

Management

Palliative Care: Focus on symptom management, comfort, and support for both patients and families 8 13.

No Specific Treatment: No curative treatment exists; management is supportive 13.

EEG Monitoring: Regular EEG to monitor disease progression and periodic complexes 14 16.

Special Populations

Pregnancy: No specific guidelines provided in the abstracts.

Pediatrics: Rare cases reported; management similar to adults 22.

Elderly: Common demographic; focus on rapid diagnosis and palliative care 8.

Comorbidities: Management should consider coexisting conditions, but specific guidance not detailed in abstracts 8.

Key Recommendations

Active Monitoring for vCJD Post-Transfusion: Continue surveillance for vCJD transmission via blood transfusion, especially in individuals with a history of blood donation or transfusion 1. (Evidence: Moderate)

Use of Disposable Instruments: Employ disposable surgical instruments, particularly in ENT procedures, to prevent iatrogenic transmission 5. (Evidence: Expert opinion)

Palliative Care Integration: Integrate palliative care early in the disease course to address symptom management and patient/family support 8. (Evidence: Moderate)

Caution with Dura Mater Grafts: Neurosurgeons should assess individual patient history for dura mater grafts to mitigate iatrogenic transmission risks 12. (Evidence: Expert opinion)

Avoidance of CNS Tissue Contamination: Exercise caution in food safety to prevent exposure to central nervous system tissues that could harbor prions 7 6. (Evidence: Moderate)

References

1 Urwin PJ, Mackenzie JM, Llewelyn CA, Will RG, Hewitt PE. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox sanguinis 2016. link 2 Schrooten M, De Vooght W, Weckhuysen S, Van Paesschen W, Van Damme P. Normalization of 14-3-3 in CJD. Acta neurologica Belgica 2008. link 3 Arnold ME, Ryan JBM, Konold T, Simmons MM, Spencer YI, Wear A et al.. Estimating the temporal relationship between PrPSc detection and incubation period in experimental bovine spongiform encephalopathy of cattle. The Journal of general virology 2007. link 4 Taylor D. Practical aspects of decontamination of the unconventional transmissible agents that cause sporadic and variant Creutzfeldt-Jakob disease and other similar human diseases. Igiene e sanita pubblica 2004. link 5 Bingham B. New variant CJD-BSE (mad cow disease). The need for disposable ENT instruments. International journal of pediatric otorhinolaryngology 2002. link00634-6) 6 Lücker E, Hardt M, Groschup MH. Detection of CNS and PrPSc in meat products. Berliner und Munchener tierarztliche Wochenschrift 2002. link 7 Lücker E, Horlacher S, Eigenbrodt E. Brain in human nutrition and variant Creutzfeldt-Jakob disease risk (vCJD): detection of brain in retail liver sausages using cholesterol and neuron specific enolase (NSE) as markers. The British journal of nutrition 2001. link 8 Bailey B, Aranda S, Quinn K, Kean H. Creutzfeldt-Jakob disease: extending palliative care nursing knowledge. International journal of palliative nursing 2000. link 9 Beaudry P, Cohen P, Brandel JP, Delasnerie-Lauprêtre N, Richard S, Launay JM et al.. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dementia and geriatric cognitive disorders 1999. link 10 v Eitzen U, Egensperger R, Kösel S, Grasbon-Frodl EM, Imai Y, Bise K et al.. Microglia and the development of spongiform change in Creutzfeldt-Jakob disease. Journal of neuropathology and experimental neurology 1998. link 11 Shabtai H, Nisipeanu P, Chapman J, Korczyn AD. Pruritus in Creutzfeldt-Jakob disease. Neurology 1996. link 12 Newcombe RL. Neurosurgery and iatrogenic transmission of Creutzfeldt-Jakob disease. The Medical journal of Australia 1996. link 13 Neatherlin JS. Creutzfeldt-Jakob disease. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 1988. link 14 Drake ME. Persistent, focal, periodic electroencephalogram discharges in Creutzfeldt-Jakob disease. Journal of the National Medical Association 1988. link 15 Kitamoto T, Tateishi J. Immunohistochemical confirmation of Creutzfeldt-Jakob disease with a long clinical course with amyloid plaque core antibodies. The American journal of pathology 1988. link 16 Malin JP, Weissenborn K, Haas J, Walter GF. Unusual EEG findings in a case of Creutzfeldt-Jakob disease. Journal of neurology 1987. link 17 Westphal KP, Schachenmayr W. Computed tomography during Creutzfeldt-Jakob disease. Neuroradiology 1985. link 18 Ishii T, Haga S, Yagishita S, Tateishi J. The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. Applied pathology 1984. link 19 Mamdani MB, Masdeu J, Ross E, Ohara R. Sleep apnea with unusual EEG changes in Jakob-Creutzfeldt disease. Electroencephalography and clinical neurophysiology 1983. link90129-3) 20 Herzberg L. Creutzfeld-Jakob disease and corneal grafts. The Medical journal of Australia 1979. link 21 Hayek J, Ulrich J. Kuru-plaques in creutzfeldt-jakob disease. European neurology 1975. link 22 Hornabrook RW, Wagner F. Creutzfeldt - Jakob disease. Papua and New Guinea medical journal 1975. link

Creutzfeldt-Jakob disease